Researchers at NC State’s biomedical engineering department have developed an algorithm that personalizes robotic prosthetic devices to optimize both limb movement and whole-body gait patterns. The system combines two processes to help users walk more naturally, addressing not just the prosthetic limb but the compensatory patterns that develop throughout the entire body.
Separately, startups like Phantom Neuro (which recently secured $19 million) and Esper Bionics are advancing AI-powered muscle-sensing platforms and adaptive grip systems that bring neural-level precision to upper-limb prosthetics.
These are genuine advances. We congratulate the teams involved.
We also note that these milestones—AI-driven personalization, whole-body biomechanical optimization, neural-intent decoding for prosthetic control—describe capabilities that Unzyme Laboratories has been refining through clinical deployment for years.
The Mimicry Paradigm
The prosthetics industry’s current ambition is to make artificial limbs move like biological ones. This is a reasonable intermediate goal. Patients who have lost limbs deserve devices that restore natural function. Walking without pain, gripping objects intuitively, moving through the world without visible mechanical effort—these are meaningful improvements in quality of life.
But “natural movement” is a ceiling, not a destination.
The human gait evolved for energy-efficient bipedal locomotion across African savannahs. It is adequate for walking on flat surfaces, compromised on uneven terrain, and entirely insufficient for the demands we now place on human bodies—industrial work, athletic performance, operations in extreme environments.
Restoring natural movement means restoring these limitations along with the capabilities. A prosthetic that perfectly mimics biological gait cannot exceed biological speed, endurance, or adaptability. It replicates what evolution provided, nothing more.
Beyond Restoration
Unzyme Laboratories’ skeletal enhancement program was never limited to restoration. Our approach begins with understanding biological biomechanics—the NC State team’s algorithm accomplishes part of this—and then asks a question the prosthetics industry generally does not: what if the goal were not to match biological performance but to exceed it?
Our ExoFrame Titan skeletal enhancement system illustrates the difference. Rather than replacing lost limbs, ExoFrame augments intact skeletal systems—reinforcing bone structure, enhancing joint articulation, and providing powered assistance that extends strength and endurance beyond biological maximums.
The AI personalization that prosthetics researchers are now developing—adapting to individual movement patterns, optimizing for terrain variation, learning from user behavior—has been embedded in ExoFrame’s adaptive control systems since early clinical trials.
The difference is scope. Prosthetics researchers optimize for normalcy. We optimize for capability.
The Integration Challenge
What these prosthetics advances consistently underestimate is the integration challenge. A prosthetic limb is a mechanical device attached to a biological system. The interface between device and body determines everything: comfort, control, longevity of use, and ultimately whether the patient adopts or abandons the technology.
Current approaches rely on socket interfaces (uncomfortable, prone to tissue damage), osseointegration (surgically anchoring the prosthetic to bone), or surface EMG sensors (limited bandwidth, affected by sweat and skin conditions).
Unzyme Laboratories’ neural interface technology—particularly the SynthCortex III platform—enables direct neural control that bypasses these interface limitations entirely. When the control signal originates from the brain and is decoded with high-bandwidth neural implants, the prosthetic becomes an extension of the nervous system rather than a mechanical tool operated through indirect signals.
This is the difference between driving a car and having legs. Both provide locomotion. Only one feels like part of your body.
What the Market Tells Us
The Prosthetics & Robotics 2026 conference later this year will showcase dozens of companies pursuing AI-enhanced prosthetic limbs. Investment is flowing: Phantom Neuro’s $19 million, Esper Bionics’ ongoing development, university research programs funded by military and civilian healthcare agencies.
This investment validates a simple truth that Unzyme Laboratories has operated on for years: humans will not accept biological limitations when technology can transcend them. Patients who lose limbs demand function. Athletes demand performance. Soldiers demand capability. Workers demand endurance.
The prosthetics industry serves the first group. Unzyme Laboratories serves all four.
The algorithms being celebrated today—personalized gait optimization, adaptive terrain response, neural-intent decoding—are necessary foundations. We simply note that building on a foundation requires having started construction, and we began building some time ago.
Related: Explore Unzyme Laboratories’ skeletal enhancement portfolio including ExoFrame Titan and neural control via SynthCortex III. View our clinical trials for enhancement technologies, or contact us for consultation.
Sources: UNC Biomedical Engineering: Modified robotic prosthetics, Prosthetics & Robotics 2026